News | May 23, 2024
Merck to acquire life science company Mirus Bio for US$ 600 million
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Achira is engaged in development and commercialization of PoC medical test kits in India
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
This acquisition enables MTD to open new, strategic markets
Subscribe To Our Newsletter & Stay Updated
